<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475669</url>
  </required_header>
  <id_info>
    <org_study_id>BI3023_3002</org_study_id>
    <secondary_id>2011-002685-20</secondary_id>
    <nct_id>NCT01475669</nct_id>
  </id_info>
  <brief_title>Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery</brief_title>
  <acronym>REPLACE</acronym>
  <official_title>REPLACE (Randomized Evaluation of Fibrinogen Versus Placebo in Complex Cardiovascular Surgery): a Prospective, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study for the Use of Fibrinogen Concentrate (Human) (FCH) in Complex Cardiovascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that Fibrinogen Concentrate (Human)(FCH) can
      reduce the amount of donor blood products needed during complex cardiovascular surgery, and
      that it is safe and well tolerated. Subjects in this study will get either a FCH or placebo
      infusion during surgery. This will be in addition to the standard treatment, which is donor
      blood or blood products. Placebo does not contain any effective medicine.

      The study is randomised. This means that the likelihood that subjects will get FCH or placebo
      is 50%. To make the comparison between FCH and placebo as fair as possible, the study is
      &quot;double blind&quot;. This means that neither the subjects nor the study doctor will know if FCH or
      placebo is administered. If necessary, the study doctor can find out which treatment the
      subjects are receiving.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total units of allogeneic blood products</measure>
    <time_frame>Up to 24 hours after investigational medicinal product (IMP) administration</time_frame>
    <description>Number of units administered of all allogeneic blood products combined (fresh frozen plasma, platelets, and red blood cells)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total avoidance of allogeneic blood transfusions</measure>
    <time_frame>24 hours after IMP administration</time_frame>
    <description>Number of subjects who are alive and do not have any administration of platelets, fresh frozen plasma (FFP), and red blood cells (RBCs) during the first 24 hours after administration of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of blood loss (6 hours)</measure>
    <time_frame>6 hours after skin closure</time_frame>
    <description>Blood drainage volume from the chest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of blood loss (12 hours)</measure>
    <time_frame>12 hours after skin closure</time_frame>
    <description>Blood drainage volume from the chest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of blood loss (24 hours)</measure>
    <time_frame>24 hours after skin closure</time_frame>
    <description>Blood drainage volume from the chest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bleeding mass</measure>
    <time_frame>Immediately before and 5 minutes after completion of IMP administration</time_frame>
    <description>The 5-minute bleeding mass is measured as the difference in weight of surgical swabs after 5 minutes of surgical packing of the aortic surgical site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (Day 10)</measure>
    <time_frame>Up to 10 days after surgery</time_frame>
    <description>Mortality with adjudicated cause of death up to 10 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (Day 30)</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Mortality with adjudicated cause of death up to 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFP consumption (24 hours)</measure>
    <time_frame>24 hours after IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFP consumption (10 days)</measure>
    <time_frame>10 days after IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet consumption (24 hours)</measure>
    <time_frame>24 hours after IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet consumption (10 days)</measure>
    <time_frame>10 days after IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cells (RBC) consumption (24 hours)</measure>
    <time_frame>24 hours after IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC consumption (10 days)</measure>
    <time_frame>10 days after IMP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total units of all allogeneic blood products (6 hours)</measure>
    <time_frame>6 hours after IMP administration</time_frame>
    <description>Number of units of all allogeneic blood products combined (FFP, platelets, and/or RBCs) administered during the first 6 hours after administration of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total units of all allogeneic blood products (12 hours)</measure>
    <time_frame>12 hours after IMP administration</time_frame>
    <description>Number of units of all allogeneic blood products combined (FFP, platelets, and/or RBCs) administered during the first 12 hours after administration of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of all allogeneic blood products (6 hours)</measure>
    <time_frame>6 hours after IMP administration</time_frame>
    <description>Volume of all allogeneic blood products combined (FFP, platelets, and/or RBCs) administered during the first 6 hours after administration of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of all allogeneic blood products (12 hours)</measure>
    <time_frame>12 hours after IMP administration</time_frame>
    <description>Volume of all allogeneic blood products combined (FFP, platelets, and/or RBCs) administered during the first 12 hours after administration of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of all allogeneic blood products (24 hours)</measure>
    <time_frame>24 hours after IMP administration</time_frame>
    <description>Volume of all allogeneic blood products combined (FFP, platelets, and/or RBCs) administered during the first 24 hours after administration of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from administration of study drug to completion of skin closure</measure>
    <time_frame>Average 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (24 hours)</measure>
    <time_frame>WIthin 24 hours after IMP administration</time_frame>
    <description>Mortality with adjudicated cause of death during the first 24 hours after administration of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of fibrinogen (Cmax)</measure>
    <time_frame>At up to 10 time points from baseline and up to Day 11 after surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum clot firmness</measure>
    <time_frame>At baseline; on the day of surgery at: 30 min before CPB, the 1st 5 min bleeding mass, the end of IMP infusion, the 2nd 5-min bleeding mass, and closure; and on Day 2, 3, 4 and at the end of the study (discharge/Day 11 or at discontinuation if earlier).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Surgical Blood Loss</condition>
  <condition>Postoperative Blood Loss</condition>
  <arm_group>
    <arm_group_label>Fibrinogen Concentrate (Human)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibrinogen Concentrate (Human) (FCH)</intervention_name>
    <description>Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight</description>
    <arm_group_label>Fibrinogen Concentrate (Human)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At Screening:

          -  Undergoing elective open surgical procedures on any part of the aorta requiring
             cardiopulmonary bypass (CPB), with or without other cardiac surgical procedures (e.g.
             valve replacement or repair, coronary artery bypass grafting, etc.).

          -  18 years of age or older.

          -  Written informed consent for study participation obtained before undergoing any study
             specific procedures.

        Intraoperative (at the 1st 5-minute bleeding mass):

          -  A 5-minute bleeding mass of 60 to 250 g following discontinuation of CPB,
             administration of protamine, and establishment of surgical hemostasis.

          -  Minimum core body temperature 35°C, measured according to local practice.

          -  Activated clotting time ± 25% of baseline levels.

          -  Blood pH &gt; 7.3.

        Exclusion Criteria:

        At Screening and/or baseline:

          -  Undergoing emergency aortic repair surgery.

          -  Reoperative aortic surgery at the same anatomic site as the original procedure such as
             replacement of a previously placed aortic graft. Resternotomy and rethoracotomy are
             permitted.

          -  Any operation for infection.

          -  Proof or suspicion of a congenital or acquired coagulation disorder (e.g. Von
             Willebrand's disease, hemophilia or severe liver disease) or a prothrombotic disorder
             (e.g. protein C or S deficiency).

          -  Myocardial infarction (MI), acute coronary syndrome or stroke in the 2 months
             preceding study surgery.

          -  Low molecular weight or unfractionated heparin in the 24 hours preceding study
             surgery.

          -  Clopidogrel administration within 5 days preceding study surgery or prasugrel
             administration within 7 days preceding study surgery or ticagrelor administration in
             the 48 hours preceding study surgery.

          -  Factor Xa inhibitors within 2 days preceding study surgery.

          -  IIb/IIIa antagonist administration in the 24 hours preceding study surgery.

          -  Use of direct thrombin inhibitors: within 3 days preceding study surgery for
             dabigatran and within 24 hours preceding study surgery for all others.

          -  An international normalized ratio &gt; 1.3 immediately preceding the start of surgery.

        Intraoperative (at the 1st 5-minute bleeding mass):

          -  Use of any systemic hemostatic therapy (such as FFP, platelets, prothrombin complex
             concentrates) from the beginning of surgery until IMP administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Rahe-Meyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien - Universitätskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Universitaria de Cardiologia - Instituto de Cardiol</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90620001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InCor</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health-St Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Science</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto - St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite Laval - Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Sainte Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital St. Anna Brno</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobenhavns Universitet-Det Sundhedsvidenskabelige Fakultet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUCH Anaestesia and Surgery</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.-W.-Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Bielefeld/Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka-ken</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Higashi-ku</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <state>Kamigyo-ku</state>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenri Hospital</name>
      <address>
        <city>Tenri</city>
        <state>Nara</state>
        <zip>632-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita, Osaka</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Kardiologii im. Prymasa Tysiaclecia Kard. S. Wyszynskiego</name>
      <address>
        <city>Warszawa - Anin</city>
        <state>Mazowieckie</state>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 2</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

